Kuros completes enrolment in phase IIb trial of bone regeneration product
This article was originally published in Clinica
Kuros Biosurgery (Zurich, Switzerland) has enrolled the final patient in a phase IIb trial of its lead bone regeneration product, KUR-111, in tibial plateau fractures. The product is a mouldable putty that is applied directly to the fracture site. The 183-patient trial will evaluate whether the material can provide physical support and promote bone healing via the release of parathyroid hormone as successfully as autografting, the current standard of care. The primary endpoint is the rate of radiological fracture healing 16 weeks after surgery. The trial will also assess the safety of KUR-111, with results expected in early 2010.